- Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow upSong, Yuqin; Zhou, Keshu; Li, Dengju; Hu, Jianda; Zou, Dehui; Gao, Sujun; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Feng, Ru; Jin, Jie; Lyu, Fangfang; Fang, Cheng; Xu, Sheng; Zhu, Jun65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled AnalysisSong, Yuqin; Zhou, Keshu; Zou, Dehui; Li, Dengju; Hu, Jianda; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Jin, Jie; Lv, Fangfang; Feng, Ru; Gao, Sujun; Zhou, Daobin; Tam, Constantine S.; Simpson, David; Wang, Michael L.; Phillips, Tycel J.; Opat, Stephen; Fang, Cheng; Sun, Shaohui; Zhu, Jun64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.被引 1
- Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 StudySong, Yuqin; Yi, Shuhua; Yang, Haiyan; Feng, Ru; Huang, Huiqiang; Zhang, Qingyuan; Liu, Yanyan; Guo, Ye; Zhang, Huilai; Zhang, Liling; Qian, Yijiao; Zhu, JianKun; Zhu, Jun65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) - Preliminary Results of Phase II CHESS Clinical Trial
2被引7阅读
